Skip to main content

Table 5 Management

From: Demographics, clinical characteristics, and outcomes among hospitalized heart failure patients across different regions of Egypt

  Total population Alexandria Cairo Delta Upper Egypt P value
Number of patients 1645 914 249 409 73  
ACEi, % 76.4 79.6 57.4 79.2 79.3 < 0.0001
ARB, % 10.1 8.5 15.5 11.5 3.5 0.1
ACEi/ARB, % 86.5 88.1 72.9 90.7 82.2 < 0.0001
BB, % 64.0 70.1 53.7 55.4 71.4 < 0.0001
MRA, % (if indicated) 78.7 71.4 82.4 88.0 90.0 0.0002
Diuretics, % 76.6 71.2 78.0 86.0 85.7 < 0.0001
CCB, % 8.3 10.5 6.1 4.7 8.8 0.003
Nitrites, % 50.5 57.9 34.9 48.0 12.3 < 0.0001
Digitalis, % 36.1 25.5 47.9 52.2 38.6 < 0.0001
Amiodarone, % 11.3 8.3 13.0 15.8 11.3 0.0002
Ivabradine, % 7.1 3.0 10.7 12.8 15.8 < 0.0001
Statins, % 70.5 80.6 50.5 65.0 31.6 < 0.0001
Anti-platlets, % 78.5 85.6 65.4 74.5 49.1 < 0.0001
Anti-coagulants, % 32.7 23.7 39.5 49.0 29.8 < 0.0001
Cardiac devices utilization
CRT indicated, % 14.0 17.5 8.2 11.3 1.5 < 0.0001
CRT planned, % 2.5 1.0 2.7 3.7 1.5 0.08
ICD indicated, % 6.6 5.2 9.1 9.3 0.0 < 0.0001
ICD planned % 1.5 0.1 2.4 2.4 0.0 0.65
  1. ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker, MRA mineralocorticoid receptor antagonist, CRT cardiac resynchronization therapy, ICD intracardiac defibrillator